HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

oligofectamine

a cationic lipid formulation used for delivery of genes, antisense oligonucleotides, and gene silencing nucleic acids

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- oligofectamine: 9

Experts

1.	Hao, Z: 1 article (08/2017)
2.	Kong, L: 1 article (08/2017)
3.	Song, X: 1 article (08/2017)
4.	Xu, X: 1 article (08/2017)
5.	Yuan, F: 1 article (08/2017)
6.	Gu, Wenyi: 1 article (02/2014)
7.	Hartono, Sandy B: 1 article (02/2014)
8.	Qiao, Shizhang: 1 article (02/2014)
9.	Strounina, Ekaterina: 1 article (02/2014)
10.	Wang, Xiaolin: 1 article (02/2014)

Related Diseases

1.	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/01/2006 - "The cell activity was detected by methyl thiazolyl tetrazolium (MTT) assay to determine the most suitable concentration, then cells were transfected into HPV18 cervical cancer cells by oligofectamine. " 08/01/2013 - "The purpose of this study is to determine whether by the use of a suitable transfection agent, it is possible to increase the efficiency of the antisense oligonucleotide targeting E6 gene, named Ru-P-4. In a recent study, we showed that Oligofectamine transfected Ru-P-4 antisense oligonucleotide failed to inhibit efficiently the growth of cervical cancer cell line SiHa, contrarily to the Ru-P-6 antisense oligonucleotide, another sequence also targeting the E6 gene. " 08/01/2013 - "PDMAEMA-b-PMEMA base polyplexes at the optimal molar ratio of polymer nitrogen atoms to DNA phosphates (N/P), were able to deliver Ru-P-4 antisense oligonucleotide and to induce a higher growth inhibition in human cervical cancer SiHa cells, compared to other formulations based on Oligofectamine."
2.	Osteosarcoma (Osteogenic Sarcoma) 03/06/2007 - "The siRNA was transfected into osteosarcoma cell line MG-63 and normal human skin fibroblast (HSF) cells via oligofectamine. " 02/07/2014 - "The PEI-Fe-LPMSN delivered siRNA-PLK1 effectively into osteosarcoma cancer cells, leading to cell viability inhibition of 80%, higher compared to the 50% reduction when the same dose of siRNA was delivered by a commercial product, oligofectamine. "
3.	Neoplasms (Cancer) 05/01/2010 - "Stereotactic injection of EGFR ASODN:FA-PAMAM complexes into established rat C6 intracranial gliomas resulted in greater suppression of tumor growth and longer survival time of tumor-bearing rats compared with PAMAM and oligofectamine-mediated EGFR-ASODN therapy. " 02/07/2014 - "The PEI-Fe-LPMSN delivered siRNA-PLK1 effectively into osteosarcoma cancer cells, leading to cell viability inhibition of 80%, higher compared to the 50% reduction when the same dose of siRNA was delivered by a commercial product, oligofectamine. "
4.	Tongue Neoplasms (Tongue Neoplasm) 02/01/2011 - "Anti-sense miRNA-21 oligonucleotide was delivered with oligofectamine to suppress Tb 3.1 tongue cancer cell growth in vitro. "
5.	Ischemia 08/15/2017 - "Experimental groups 1. Control group; 2. Ischemia-repefusion group (I/R group); 3. Oligofectamine group (Oli group); 4. Oligofectamine and antisense oligodeoxynucleotide (AS-ODN) group (As group); 5. Oligofectamine and missense oligodeoxynucleotide (MS-ODN) group (Ms group); 6. SP600125 and Oligofectamine and AS-ODN group (SP600125/As group); 7. SP600125 and Oligofectamine and MS-ODN group (SP600125/Ms group). "

Related Drugs and Biologics

1.	Antisense Oligonucleotides
2.	Small Interfering RNA (siRNA)
3.	Oligodeoxyribonucleotides
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Catalytic DNA (Deoxyribozyme)
6.	Polymers
7.	Phosphates (Orthophosphate)
8.	Oligonucleotides
9.	Nitrogen
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics